Magically transforms $0.50 GAAP EPS to $2 non-GAAP by liberally excluding recurring operating expenses. Look at the free cash flow. Only about $4 per share. Put a 20x multiple and this is a $80 stock.
Actavis doesn't cheat. They grow, but don't cheat. Before long it will be the number one generic pharmaceutical equity.
Sentiment: Strong Buy
Well, you haven't disputed any of the figures I put out. Look at the free cash flow and the liberal non-GAAP exclusions. Momentum can carry a stock only so far before the inevitable painful crash.